CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (USD $)	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
Cash flows from operating activities:
Net loss	$ (1,837,721)	$ (5,851,067)
Adjustments to reconcile net loss to net cash flows from operating activities:
Depreciation	231,491	231,862
Amortization of intangible assets	667,954	667,954
Amortization of debt discount and deferred financing costs	783,226	133,517
Employee share-based compensation expense	878,491	809,469
Other share-based compensation expense	207,709	222,208
Increase (decrease) in cash resulting from changes in (net of effects of acquisition):
Accounts receivable	(2,054,414)	(559,044)
Inventory	(249,337)	(103,257)
Prepaid expenses and other current assets	(127,559)	(140,508)
Accounts payable and accrued expenses	(338,636)	574,521
Accrued interest	232,107	37,698
Other liabilities	7,878	57,127
Net cash flows from operating activities	(1,598,811)	(3,919,520)
Cash flows from investing activities:
Purchases of equipment	(238,498)	(143,427)
Cash paid for acquisition, net of cash acquired of $33,583	0	(466,417)
Net cash flows from investing activities	(238,498)	(609,844)
Cash flows from financing activities:
Proceeds from exercise of warrants	323,638	0
Proceeds from exercise of stock options	315,295	3
Repayment of Convertible Debt related to acquisition	(250,000)	0
Repayment of Equipment Lease	(9,256)	0
Proceeds from Line of Credit with related party	0	1,300,000
Repayment of Line of Credit	0	(99,000)
Repayment of Notes Payable	0	(30,932)
Proceeds from sale of common stock and warrants and common stock with registration rights, net	0	3,632,721
Net cash flows from financing activities	379,677	4,802,792
Net change in cash	(1,457,632)	273,428
Cash, beginning of period	4,112,326	1,340,922
Cash, end of period	2,654,694	1,614,350
Supplemental disclosure of cash flow information:
Cash paid for interest	5,435	2,833
Cash paid for income taxes	0	0
Supplemental disclosure of non-cash financing activity:
Common stock issued for accrued Director fees	184,653
Common stock issued for accrued Director fees (in shares)	167,086
Cashless exercise of warrants (in shares)	167,183
Deferred financing costs	9,537
Beneficial conversion feature recognized	514,456	80,000
Shares issued for conversion of convertible debt and accrued interest to equity (in shares)		406,664
Shares issued in conjunction with the acquisition of Surgical Biologics, LLC (in shares)		5,250,000
Stock valued in conjunction with the acquisition of Surgical Biologics, LLC		7,087,500
Beneficial conversion feature value related to the convertible debt issued with regard to the acquisition of Surgical Biologics, LLC		437,500
Convertible debt issued with regard to acquisition of Surgical Biologics		1,250,000
Stock valued for payment of earn out liability related to acquisition of Surgical Biologics, LLC	3,185,223
Stock valued for payment of earn out liability related to acquisition of Surgical Biologics, LLC (in shares)	2,632,576
Equipment acquired under capital lease	$ 72,302